Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
08 Mai 2023 - 2:00PM
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the
“Company”), a clinical stage biopharmaceutical company focused on
developing novel synthetic lethality-based cancer therapeutics
targeting DNA damage response (DDR) pathways, today announced the
appointment of Gabriela Gruia, M.D. to its Board of Directors,
effective as of May 5, 2023. Dr. Gruia joins Aprea with over 25
years of clinical, regulatory and life science leadership
experience.
“We are honored to welcome Dr. Gruia to the Aprea Board of
Directors, where her deep experience and accomplishments in drug
development and regulatory affairs will be of immense importance in
advancing and expanding our pipeline of synthetic lethality
inhibitors,” said Oren Gilad, Ph.D., President and Chief Executive
Officer of Aprea. “Dr. Gruia’s proven skills in executing
successful drug development strategies will provide valuable
support to our growing pipeline, as we look ahead to upcoming
milestones, including continued advancement of our lead candidate,
ATRN-119, currently in a Phase 1/2a monotherapy trial for the
treatment of cancers with DDR mutations.”
Dr. Gruia currently serves as Principal at Gabriela Gruia
Consulting, LLC, which she founded in January 2021. She also serves
as an Independent Board Director at Tessa Therapeutics, TScan
Therapeutics, and Molecular Templates. Prior to her time as a
consultant, Dr. Gruia served as the Chief Development Officer at
Ichnos Sciences Inc. where she led clinical development activities.
Prior to that, she was Senior Vice President and Head of Drug
Regulatory Affairs for Novartis Oncology, where she led an oncology
regulatory affairs organization which oversaw worldwide regulatory
submissions and approvals of twelve molecular oncological entities,
and over 100 sNDAs and MAAs. Previously, Dr. Gruia held leadership
roles in research and development at Novartis, Pfizer, Pharmacia,
Aventis and Rhone Poulenc. Dr. Gruia received her M.D. from
Bucharest Medical School in Romania and a Masters in Breast
Pathology and Mammography from Rene Huguenin/Curie Institute Cancer
Center in Paris, France. She received her training in oncology and
hematology from Rene Descartes University in Paris, France.
“I am thrilled to join Aprea at this pivotal moment in the
company’s growth. I was impressed by Aprea’s approach to cancer
therapy using synthetic lethality, and I look forward to applying
my expertise in R&D and regulatory affairs to help grow this
promising pipeline of synthetic lethality inhibitors, and poise the
company for success with regulatory agencies,” said Dr. Gruia. “I
share Aprea’s mission and commitment to addressing unmet medical
needs for patients suffering from cancers.”
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a clinical stage biopharmaceutical
company headquartered in Doylestown, Pennsylvania, focused on
developing and commercializing novel synthetic lethality-based
cancer therapeutics targeting a critical pathway and some of the
most central targets in DDR and cancer progression. The Company’s
lead program is ATRN-119, a clinical-stage small molecule ATR
inhibitor being developed for solid tumor indications. Our WEE1
inhibitor is being advanced to IND submission. For more
information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations
website at https://ir.aprea.com/ as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD.
Forward Looking Statement
Certain information contained in this press release includes
“forward-looking statements”, within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, related to our study
analyses, clinical trials, regulatory submissions, and projected
cash position. We may, in some cases use terms such as “future,”
“predicts,” “believes,” “potential,” “continue,” “anticipates,”
“estimates,” “expects,” “plans,” “intends,” “targeting,”
“confidence,” “may,” “could,” “might,” “likely,” “will,” “should”
or other words that convey uncertainty of the future events or
outcomes to identify these forward-looking statements. Our
forward-looking statements are based on current beliefs and
expectations of our management team and on information currently
available to management that involve risks, potential changes in
circumstances, assumptions, and uncertainties. All statements
contained in this press release other than statements of historical
fact are forward-looking statements, including statements regarding
our ability to develop, commercialize and achieve market acceptance
of our current and planned products and services, our research and
development efforts, and other matters regarding our business
strategies, use of capital, results of operations and financial
position, and plans and objectives for future operations. Any or
all of the forward-looking statements may turn out to be wrong or
be affected by inaccurate assumptions we might make or by known or
unknown risks and uncertainties. These forward-looking statements
are subject to risks and uncertainties including risks related to
the success and timing of our clinical trials or other studies,
risks associated with the coronavirus pandemic and the other risks
set forth in our filings with the U.S. Securities and Exchange
Commission. For all these reasons, actual results and developments
could be materially different from those expressed in or implied by
our forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements, which are made
only as of the date of this press release. We undertake no
obligation to update such forward-looking statements for any
reason, except as required by law.
Source: Aprea Therapeutics, Inc.
Investors and Media:
aprea@argotpartners.com212-600-1902
Aprea Therapeutics (NASDAQ:APRE)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Aprea Therapeutics (NASDAQ:APRE)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024